2025 France Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 France Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Gene Therapy market in France include OSE Immunotherapeutics, Pierre Fabre Group, Coave Therapeutics, and Cellectis. OSE Immunotherapeutics is a biotech company developing first-in-class cancer immunotherapies based on immune cells, focusing on innovative treatments for cancer and inflammatory diseases. Pierre Fabre Group, one of France’s largest pharmaceutical groups, is involved in oncology drug development and manufactures extensively in France, with significant R&D investment and a strong presence in dermo-pharma and oncology sectors. Coave Therapeutics specializes in gene therapies for inherited retinal and CNS diseases, including cancer-related targets, and is advancing proprietary gene therapy platforms. Cellectis is a clinical-stage company focused on next-generation CAR T-cell therapies aimed at curing cancer in France and globally.
These companies contribute to France’s growing cancer gene therapy landscape, supported by a robust biotech ecosystem and increasing regulatory and investment activity. Forecasts predict a rapid rise in cell and gene therapy launches treating oncology indications in France by 2030, positioning firms like these to play key roles in expanding patient access to transformative therapies. The developments include novel CAR T-cell therapies, viral vector innovations, and expanding clinical trials targeting solid tumors and hematological malignancies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Gene Therapy market in France include OSE Immunotherapeutics, Pierre Fabre Group, Coave Therapeutics, and Cellectis. OSE Immunotherapeutics is a biotech company developing first-in-class cancer immunotherapies based on immune cells, focusing on innovative treatments for cancer and inflammatory diseases. Pierre Fabre Group, one of France’s largest pharmaceutical groups, is involved in oncology drug development and manufactures extensively in France, with significant R&D investment and a strong presence in dermo-pharma and oncology sectors. Coave Therapeutics specializes in gene therapies for inherited retinal and CNS diseases, including cancer-related targets, and is advancing proprietary gene therapy platforms. Cellectis is a clinical-stage company focused on next-generation CAR T-cell therapies aimed at curing cancer in France and globally.
These companies contribute to France’s growing cancer gene therapy landscape, supported by a robust biotech ecosystem and increasing regulatory and investment activity. Forecasts predict a rapid rise in cell and gene therapy launches treating oncology indications in France by 2030, positioning firms like these to play key roles in expanding patient access to transformative therapies. The developments include novel CAR T-cell therapies, viral vector innovations, and expanding clinical trials targeting solid tumors and hematological malignancies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
